BioSpace News Archive

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced positive interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib in patients with ER+ metastatic breast cancer.

Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, announced first monotherapy clinical data from its Phase 1 study of CLN-619 in patients with advanced solid tumors.

Biotheryx, Inc. announced two poster presentations at the 2023 American Society of Clinical Oncology Annual Meeting, being held June 2–6, 2023, in Chicago, Illinois and online.

Pionyr Immunotherapeutics, Inc. announced that PY159, a monoclonal antibody targeting TREM1, was well-tolerated with signals of durable therapeutic activity in a Phase 1a dose-escalation study as a single agent and in combination with pembrolizumab.

Structure Therapeutics Inc. announced that it has dosed the first patient in its Phase 2a study of its highly selective oral GLP-1 agonist GSBR-1290 in adults who are overweight or obese and otherwise healthy, and in adults with type 2 diabetes mellitus who are overweight or obese.

Takeda and HUTCHMED Limited announced that the U.S. Food and Drug Administration has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer.

Evaxion Biotech A/S unveils the technology behind its novel, proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced the publication of three abstracts on the American Society of Clinical Oncology website.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, announced updated results from Phase 2 of the RINGSIDE study evaluating AL102 in desmoid tumors.

Replimune Group, Inc. announced multiple presentations at the 2023 American Society of Clinical Oncology Annual Meeting being held in Chicago, IL from June 2-6, 2023.